CytRx Announces Research And Development Day And Webcast
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that the
Company will host a Research and Development Day on Friday, May 2, from
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company will host a Research and Development Day on Friday, May 2, from 8:30 – 11:30 am EDT at the Harvard Club in New York City. The event, which will be open to analysts and institutional investors, will include presentations by, and a panel discussion with, key opinion leaders in oncology and sarcoma, including the principal investigator for the Company’s pivotal, global Phase 3 trial of aldoxorubicin in patients with soft tissue sarcoma. Breakfast will be served. Please RSVP to firstname.lastname@example.org. CytRx invites the public and the media to join the event via the webcast. Speakers scheduled to present include: Daniel Von Hoff, M.D., F.A.C.P. Dr. Von Hoff currently serves as Physician in Chief and Director of the Translational Genomics Research Institute (TGEN) in Phoenix, Arizona. He is also Chief Scientific Officer for the US Oncology Network, one of the nation’s largest networks of community-based oncology physicians dedicated to advancing cancer care in America. He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA's Oncology Advisory Committee. Dr. Von Hoff is a past president of the American Association for Cancer Research, was on the AACR and the American Society of Clinical Oncology's Board of Directors, and is a fellow of the American College of Physicians. He is the founder of Investigational New Drugs - The Journal of New Anticancer Agents and is currently editor-in-chief of Molecular Cancer Therapeutics. Sant Chawla, M.D., F.R.A.C.P. Dr. Chawla is the Principal Investigator for the aldoxorubicin global Phase 3 pivotal trial in second-line soft tissue sarcoma. He was the Principal Investigator for the Phase 2b and Phase 1b/2 clinical trials with aldoxorubicin. Dr. Chawla currently serves as Director of Medical Oncology at the UCLA-Santa Monica Hospital, Director of Medical Oncology at Orthopaedic Hospital, and as Director of Medical Oncology at Century City Hospital. Dr. Chawla also currently heads the Sarcoma Oncology Center in Santa Monica, CA. Following completion of his medical degree and residency training at the All India Institute of Medical Sciences in New Delhi, Dr. Chawla completed a fellowship in medical oncology in New Zealand, at the Fellow Royal Australasian College of Physicians (F.R.A.C.P.), and later, in recognition for his outstanding academic accomplishments, he was invited to continue his fellowship in oncology at the prestigious M.D. Anderson Cancer Center of the University of Texas.